Balamrit Singh Sokhal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Balamrit Singh Sokhal has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Mamas Andreas Mamas
Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, United Kingdom; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, United Kingdom
9 shared publications - Christian David Mallen
Keele Staffordshire ST5 5BG School of Medicine and Centre for Musculoskeletal Health Research , Keele University
7 shared publications Andrija Matetić
Keele Cardiovascular Research Group, Centre for Prognosis Research Keele University Keele UK
6 shared publications- Sara Muller
School of Medicine, Keele University , Keele
5 shared publications Sowmya Prasanna Kumar Menon
Keele University School of Medicine, Keele, England
5 shared publications- Andrija Matetic
Department of Cardiology, University Hospital of Split, 21000 Split, Croatia
4 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7503
Validation and Performance of Five Upper Gastrointestinal Bleeding Prognostication Scores in a Single-Centre United Kingdom Cohort of over 1000 Patients
Objectives: Upper gastrointestinal bleeding (UGIB) is a common medical emergency associated with substantial morbidity and mortality. Several clinical risk scores are available, but their comparative performance across outcomes and patient subgroups remains uncertain. We compared five established UGIB risk scores for predicting inpatient mortality and complications in a large United Kingdom (UK) cohort and evaluated performance according to bleeding aetiology and sex. We also explored the incremental prognostic value of body mass index (BMI). Methods: We conducted a retrospective cohort study of 1003 hospitalised patients with UGIB who underwent oesophagogastroduodenoscopy at a UK tertiary centre (2023–2025). Five risk scores were evaluated: age, blood tests, and comorbidities (ABC); mental status–anaesthesiologist score–pulse–albumin–systolic blood pressure–haemoglobin (MAP(ASH)), Charlson comorbidity index–hospital-onset–albumin–mental status–Eastern Cooperative Oncology Group performance status–steroids (CHAMPS), Glasgow–Blatchford score (GBS), and the Japanese score. The primary outcome was inpatient mortality, and the secondary outcome was an inpatient complication composite comprising rebleeding, repeat endoscopy, or interventional radiology. Discrimination was assessed using area under the receiver operating characteristic curves (AUROCs), with pairwise comparisons using the DeLong test. BMI was evaluated using multivariable regression and AUROC analysis. Results: ABC demonstrated the highest numerical discrimination for inpatient mortality (AUROC 0.817), followed by CHAMPS (0.791) and MAP(ASH) (0.774), with no statistically significant differences between these three scores. For inpatient complications, MAP(ASH) had the highest numerical AUROC (0.697), although its performance did not differ significantly from CHAMPS, GBS, or ABC. Exploratory subgroup analyses demonstrated generally good mortality discrimination for ABC and CHAMPS across bleeding aetiology and sex. Adding BMI to ABC increased the AUROC from 0.817 to 0.828, although this was not statistically significant (p = 0.224). Conclusions: ABC, CHAMPS, and MAP(ASH) demonstrated the strongest discrimination for inpatient mortality, while discrimination for inpatient complications was more modest across scores. These findings do not establish the clinical superiority of a single scoring system, and BMI did not provide significant incremental prognostic value.
- 27 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7503
Open AccessValidation and Performance of Five Upper Gastrointestinal Bleeding Prognostication Scores in a Single-Centre United Kingdom Cohort of over 1000 Patients
Objectives: Upper gastrointestinal bleeding (UGIB) is a common medical emergency associated with substantial morbidity and mortality. Several clinical risk scores are available, but their comparative performance across outcomes and patient subgroups remains uncertain. We compared five established UGIB risk scores for predicting inpatient mortality and complications in a large United Kingdom (UK) cohort and evaluated performance according to bleeding aetiology and sex. We also explored the incremental prognostic value of body mass index (BMI). Methods: We conducted a retrospective cohort study of 1003 hospitalised patients with UGIB who underwent oesophagogastroduodenoscopy at a UK tertiary centre (2023–2025). Five risk scores were evaluated: age, blood tests, and comorbidities (ABC); mental status–anaesthesiologist score–pulse–albumin–systolic blood pressure–haemoglobin (MAP(ASH)), Charlson comorbidity index–hospital-onset–albumin–mental status–Eastern Cooperative Oncology Group performance status–steroids (CHAMPS), Glasgow–Blatchford score (GBS), and the Japanese score. The primary outcome was inpatient mortality, and the secondary outcome was an inpatient complication composite comprising rebleeding, repeat endoscopy, or interventional radiology. Discrimination was assessed using area under the receiver operating characteristic curves (AUROCs), with pairwise comparisons using the DeLong test. BMI was evaluated using multivariable regression and AUROC analysis. Results: ABC demonstrated the highest numerical discrimination for inpatient mortality (AUROC 0.817), followed by CHAMPS (0.791) and MAP(ASH) (0.774), with no statistically significant differences between these three scores. For inpatient complications, MAP(ASH) had the highest numerical AUROC (0.697), although its performance did not differ significantly from CHAMPS, GBS, or ABC. Exploratory subgroup analyses demonstrated generally good mortality discrimination for ABC and CHAMPS across bleeding aetiology and sex. Adding BMI to ABC increased the AUROC from 0.817 to 0.828, although this was not statistically significant (p = 0.224). Conclusions: ABC, CHAMPS, and MAP(ASH) demonstrated the strongest discrimination for inpatient mortality, while discrimination for inpatient complications was more modest across scores. These findings do not establish the clinical superiority of a single scoring system, and BMI did not provide significant incremental prognostic value.
- 15 September 2026
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 56 (9)
Prevalence of Cancer Across Cardiovascular and Cardiometabolic Conditions: A Systematic Review and Meta‐Analysis
Background: To the best of our knowledge, no previous systematic review has comprehensively quantified cancer prevalence across the broad spectrum of cardiovascular and cardiometabolic conditions included in the present study. We aimed to estimate pooled prevalence of active cancer (primary outcome) and other cancer categories among patients with coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), hypertension, Type 2 diabetes mellitus (DM), stroke, peripheral artery disease (PAD), and valvular heart disease (VHD). Methods: PubMed, Web of Science, and Scopus were searched from 2010 to July 2024. Secondary outcomes included prevalence of any, previous, haematological, solid, and metastatic cancer. Prevalence estimates were calculated using one‐step generalized linear mixed models. Results: A total of 676 studies comprising approximately 180 million participants were included. The primary analysis of active cancer included 59 studies (4,759,695 patients). Active cancer prevalence ranged from 4.22% (95% confidence interval [CI] 2.18–5.32) in Type 2 DM to 5.55% (95% CI 3.97–7.01) in AF. The prevalence of any cancer, a secondary outcome with more heterogeneous ascertainment, ranged from 7.04% (95% CI 6.05–8.03) in CAD to 14.10% (95% CI 12.20–15.99) in AF. Conclusion: Cancer represents a substantial comorbidity across cardiovascular and cardiometabolic conditions. Although cancer ascertainment methods varied across studies, particularly for any cancer, the findings provide contemporary estimates of cancer burden that may inform future cardio‐oncology research, healthcare planning, risk stratification, and the design of cardiovascular and cardiometabolic clinical trials. Trial Registration: PROSPERO CRD42023494764
- 15 September 2026
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 56 (9)
Prevalence of Cancer Across Cardiovascular and Cardiometabolic Conditions: A Systematic Review and Meta‐Analysis
Background: To the best of our knowledge, no previous systematic review has comprehensively quantified cancer prevalence across the broad spectrum of cardiovascular and cardiometabolic conditions included in the present study. We aimed to estimate pooled prevalence of active cancer (primary outcome) and other cancer categories among patients with coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), hypertension, Type 2 diabetes mellitus (DM), stroke, peripheral artery disease (PAD), and valvular heart disease (VHD). Methods: PubMed, Web of Science, and Scopus were searched from 2010 to July 2024. Secondary outcomes included prevalence of any, previous, haematological, solid, and metastatic cancer. Prevalence estimates were calculated using one‐step generalized linear mixed models. Results: A total of 676 studies comprising approximately 180 million participants were included. The primary analysis of active cancer included 59 studies (4,759,695 patients). Active cancer prevalence ranged from 4.22% (95% confidence interval [CI] 2.18–5.32) in Type 2 DM to 5.55% (95% CI 3.97–7.01) in AF. The prevalence of any cancer, a secondary outcome with more heterogeneous ascertainment, ranged from 7.04% (95% CI 6.05–8.03) in CAD to 14.10% (95% CI 12.20–15.99) in AF. Conclusion: Cancer represents a substantial comorbidity across cardiovascular and cardiometabolic conditions. Although cancer ascertainment methods varied across studies, particularly for any cancer, the findings provide contemporary estimates of cancer burden that may inform future cardio‐oncology research, healthcare planning, risk stratification, and the design of cardiovascular and cardiometabolic clinical trials. Trial Registration: PROSPERO CRD42023494764
- Open Access
“Prevalence of cancer in patients with cardiovascular diseases and risk factors: a systematic review and meta-analysis”
Background: No systematic review has been conducted to pool the existing evidence and quantify cancer prevalence rates in cardiovascular diseases (CVDs). We aimed to estimate pooled cancer prevalence in coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), hypertension, type 2 diabetes mellitus (DM), stroke, peripheral arterial disease (PAD), and valvular heart diseases (VHD). Methods: PubMed, Web of Science, and Scopus were searched from 2010 to July 2024. The outcomes were proportions of patients with active, any, previous, blood, solid, and metastatic cancer. The prevalence rates were estimated via one-step generalized linear mixed models. Results: Totally, we retrieved 676 studies with enrollment of roughly 180 million participants. The analysis for active cancer included 59 studies with a population of 4,759,695 patients. The pooled prevalence of active cancer was 4.22% (95% confidence interval (CI) 2.18-5.32), 4.43% (95% CI 2.78-6.38), 4.60% (95% CI 1.72-8.13), 4.61% (95% CI, 2.83-6.97), 4.90% (95% CI 3.84-6.37), and 5.55% (95% CI 3.97-7.01) in patients with type 2 DM, chronic HF, any stroke, CAD, VHD, and AF. For any cancer, prevalence rates ranged from 14.10% (95% CI 12.20-15.99) in AF to 7.04% (95% CI 6.05-8.03) in CAD. Conclusion: Pooled prevalence rates demonstrate a measurable burden of cancer among patients with a wide range of CVDs, highlighting the need for multidisciplinary management in this population. Registration: PROSPERO CRD42023494764
Open Access“Prevalence of cancer in patients with cardiovascular diseases and risk factors: a systematic review and meta-analysis”
Background: No systematic review has been conducted to pool the existing evidence and quantify cancer prevalence rates in cardiovascular diseases (CVDs). We aimed to estimate pooled cancer prevalence in coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), hypertension, type 2 diabetes mellitus (DM), stroke, peripheral arterial disease (PAD), and valvular heart diseases (VHD). Methods: PubMed, Web of Science, and Scopus were searched from 2010 to July 2024. The outcomes were proportions of patients with active, any, previous, blood, solid, and metastatic cancer. The prevalence rates were estimated via one-step generalized linear mixed models. Results: Totally, we retrieved 676 studies with enrollment of roughly 180 million participants. The analysis for active cancer included 59 studies with a population of 4,759,695 patients. The pooled prevalence of active cancer was 4.22% (95% confidence interval (CI) 2.18-5.32), 4.43% (95% CI 2.78-6.38), 4.60% (95% CI 1.72-8.13), 4.61% (95% CI, 2.83-6.97), 4.90% (95% CI 3.84-6.37), and 5.55% (95% CI 3.97-7.01) in patients with type 2 DM, chronic HF, any stroke, CAD, VHD, and AF. For any cancer, prevalence rates ranged from 14.10% (95% CI 12.20-15.99) in AF to 7.04% (95% CI 6.05-8.03) in CAD. Conclusion: Pooled prevalence rates demonstrate a measurable burden of cancer among patients with a wide range of CVDs, highlighting the need for multidisciplinary management in this population. Registration: PROSPERO CRD42023494764
- 30 June 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (10) , 103390
Implantable cardioverter-defibrillator in cardiac sarcoidosis: A propensity-score matched analysis
- 30 June 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (10) , 103390
Implantable cardioverter-defibrillator in cardiac sarcoidosis: A propensity-score matched analysis
- 23 June 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (8) , 2278-2285
Workforce Perception and Awareness of Sustainability in Gastrointestinal Endoscopy: A Systematic Review of Green Endoscopy
Background: Gastrointestinal (GI) endoscopy is a high‐throughput, resource‐intensive specialty with a substantial environmental impact. As healthcare systems move toward sustainability, the concept of “green endoscopy” (GE) has gained traction. However, the perceptions and engagement of the endoscopy workforce remain underexplored. Objective: This systematic review aimed to evaluate awareness, attitudes, and perceived barriers among healthcare professionals regarding sustainability in endoscopy and to synthesize existing knowledge on workforce engagement with GE practices. Methods: A systematic search of PubMed, Embase, and the Cochrane Library was conducted up to April 1, 2025, supplemented by gray literature. Included studies reported original data on healthcare professionals' knowledge, attitudes, or practices related to sustainable endoscopy. Due to heterogeneity, a synthesis without meta‐analysis (SWiM) approach was used. Results: Five cross‐sectional studies involving 1684 participants across various regions were included. Awareness of GE ranged from 16.3% to 67%. While most respondents acknowledged the environmental burden of endoscopy, fewer reported institutional guidelines or training. Key barriers included lack of knowledge (35%), absence of institutional policy (32%), infection control concerns (41%), and financial constraints (26%). Few departments conducted audits or offered sustainability education. A generational divide was noted, with senior staff expressing greater environmental concern. Conclusion: Although global interest in sustainable endoscopy is rising, a significant gap exists between awareness and practice. Structured education, clear institutional policies, and support from professional bodies are essential to embed sustainability within endoscopy services.
- 23 June 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (8) , 2278-2285
Workforce Perception and Awareness of Sustainability in Gastrointestinal Endoscopy: A Systematic Review of Green Endoscopy
Background: Gastrointestinal (GI) endoscopy is a high‐throughput, resource‐intensive specialty with a substantial environmental impact. As healthcare systems move toward sustainability, the concept of “green endoscopy” (GE) has gained traction. However, the perceptions and engagement of the endoscopy workforce remain underexplored. Objective: This systematic review aimed to evaluate awareness, attitudes, and perceived barriers among healthcare professionals regarding sustainability in endoscopy and to synthesize existing knowledge on workforce engagement with GE practices. Methods: A systematic search of PubMed, Embase, and the Cochrane Library was conducted up to April 1, 2025, supplemented by gray literature. Included studies reported original data on healthcare professionals' knowledge, attitudes, or practices related to sustainable endoscopy. Due to heterogeneity, a synthesis without meta‐analysis (SWiM) approach was used. Results: Five cross‐sectional studies involving 1684 participants across various regions were included. Awareness of GE ranged from 16.3% to 67%. While most respondents acknowledged the environmental burden of endoscopy, fewer reported institutional guidelines or training. Key barriers included lack of knowledge (35%), absence of institutional policy (32%), infection control concerns (41%), and financial constraints (26%). Few departments conducted audits or offered sustainability education. A generational divide was noted, with senior staff expressing greater environmental concern. Conclusion: Although global interest in sustainable endoscopy is rising, a significant gap exists between awareness and practice. Structured education, clear institutional policies, and support from professional bodies are essential to embed sustainability within endoscopy services.
- Open Access
- 24 October 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (4) , 1232-1252
Artificial Intelligence in Population-Level Gastroenterology and Hepatology: A Comprehensive Review of Public Health Applications and Quantitative Impact
Background: Artificial intelligence (AI), which includes machine learning and deep learning, is fundamentally changing public health in gastroenterology and hepatology—fields grappling with a significant global disease burden. Objective: This review focuses on the population-level applications and impact of AI, highlighting its role in shifting healthcare strategies from reactive treatment to proactive prevention. Results: AI demonstrates substantial improvements across many different areas. In colorectal cancer, AI models significantly boost detection rates, successfully identifying a large majority of high-risk individuals often missed by traditional screening methods. For metabolic dysfunction-associated steatotic liver disease (MASLD), advanced non-invasive tests offer a high degree of reliability in detecting liver fibrosis. The identification of viral hepatitis is enhanced with excellent accuracy, and gastrointestinal infection surveillance benefits from wastewater analysis that provides an early warning system weeks ahead of clinical case reporting. Furthermore, AI improves the diagnosis of upper GI cancers, such as gastric cancer, with higher diagnostic capability, and facilitates precision public health in inflammatory bowel disease (IBD) through highly accurate risk prediction models. Challenges: Despite these important advances, significant hurdles remain. Key challenges include ensuring diverse and representative data to prevent algorithmic bias, protecting patient privacy, establishing robust regulatory frameworks for new technologies, and successfully moving innovations from research settings into practical, real-world deployment. Conclusion: The unequal distribution of AI development and access between high-income countries and low- and middle-income countries risks exacerbating existing health disparities. To fully realize AI's transformative potential for global public health in gastroenterology and hepatology, these cross-cutting issues must be actively addressed through ethical design, rigorous validation, and equitable worldwide deployment.
- 24 October 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (4) , 1232-1252
Open AccessArtificial Intelligence in Population-Level Gastroenterology and Hepatology: A Comprehensive Review of Public Health Applications and Quantitative Impact
Background: Artificial intelligence (AI), which includes machine learning and deep learning, is fundamentally changing public health in gastroenterology and hepatology—fields grappling with a significant global disease burden. Objective: This review focuses on the population-level applications and impact of AI, highlighting its role in shifting healthcare strategies from reactive treatment to proactive prevention. Results: AI demonstrates substantial improvements across many different areas. In colorectal cancer, AI models significantly boost detection rates, successfully identifying a large majority of high-risk individuals often missed by traditional screening methods. For metabolic dysfunction-associated steatotic liver disease (MASLD), advanced non-invasive tests offer a high degree of reliability in detecting liver fibrosis. The identification of viral hepatitis is enhanced with excellent accuracy, and gastrointestinal infection surveillance benefits from wastewater analysis that provides an early warning system weeks ahead of clinical case reporting. Furthermore, AI improves the diagnosis of upper GI cancers, such as gastric cancer, with higher diagnostic capability, and facilitates precision public health in inflammatory bowel disease (IBD) through highly accurate risk prediction models. Challenges: Despite these important advances, significant hurdles remain. Key challenges include ensuring diverse and representative data to prevent algorithmic bias, protecting patient privacy, establishing robust regulatory frameworks for new technologies, and successfully moving innovations from research settings into practical, real-world deployment. Conclusion: The unequal distribution of AI development and access between high-income countries and low- and middle-income countries risks exacerbating existing health disparities. To fully realize AI's transformative potential for global public health in gastroenterology and hepatology, these cross-cutting issues must be actively addressed through ethical design, rigorous validation, and equitable worldwide deployment.
- Open Access
- 23 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (6) , oeaf139
The quality of care and long-term mortality of patients with ST-elevation myocardial infarction and cardiac devices: a nationwide cohort study
Introduction: There is a growing population with cardiac devices (pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy), but whether this influences quality of care and long-term mortality after ST-elevation myocardial infarction (STEMI) is unknown. Methods and results: Patients in England and Wales between January 2005 and March 2019 with a diagnosis of STEMI were included from the Myocardial Ischaemia National Audit Project, Hospital Episode Statistics and mortality linkage to July 2021. Primary outcomes were all-cause mortality over the study period, secondary outcomes were odds of undergoing reperfusion within guideline mandated timeframes. Multivariate cox-models compared all-cause mortality over specified time-periods and logistic regression models illustrated odds of undergoing reperfusion. 322 890 patients with STEMI were included, 2118 (0.7%) had a cardiac device at STEMI admission. Patients with cardiac devices were older (78 years old vs. 66 years old) and more often female (32% vs. 29%) (P < 0.001). After multivariate adjustment, patients with cardiac devices were less likely to have a ‘door-to-balloon time’ of under 60 min (aOR 0.61 95% CI 0.54–0.70) (P < 0.001). Patients with cardiac devices had an increased risk of all-cause mortality at 5-years (aHR 1.12 95% CI 1.05–1.20) (P < 0.001). Excluding patients dying within 30 days of admission, patients with cardiac devices still had a higher risk of death at 5-years (aHR 1.23 95% CI 1.13–1.33) (all P < 0.001). Conclusion: Patients with cardiac devices were less likely to undergo revascularization for STEMI within guideline mandated timeframes. They remain at elevated risk of all-cause mortality up to 5-years compared with STEMI patients without cardiac devices.
- 23 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (6) , oeaf139
Open AccessThe quality of care and long-term mortality of patients with ST-elevation myocardial infarction and cardiac devices: a nationwide cohort study
Introduction: There is a growing population with cardiac devices (pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy), but whether this influences quality of care and long-term mortality after ST-elevation myocardial infarction (STEMI) is unknown. Methods and results: Patients in England and Wales between January 2005 and March 2019 with a diagnosis of STEMI were included from the Myocardial Ischaemia National Audit Project, Hospital Episode Statistics and mortality linkage to July 2021. Primary outcomes were all-cause mortality over the study period, secondary outcomes were odds of undergoing reperfusion within guideline mandated timeframes. Multivariate cox-models compared all-cause mortality over specified time-periods and logistic regression models illustrated odds of undergoing reperfusion. 322 890 patients with STEMI were included, 2118 (0.7%) had a cardiac device at STEMI admission. Patients with cardiac devices were older (78 years old vs. 66 years old) and more often female (32% vs. 29%) (P < 0.001). After multivariate adjustment, patients with cardiac devices were less likely to have a ‘door-to-balloon time’ of under 60 min (aOR 0.61 95% CI 0.54–0.70) (P < 0.001). Patients with cardiac devices had an increased risk of all-cause mortality at 5-years (aHR 1.12 95% CI 1.05–1.20) (P < 0.001). Excluding patients dying within 30 days of admission, patients with cardiac devices still had a higher risk of death at 5-years (aHR 1.23 95% CI 1.13–1.33) (all P < 0.001). Conclusion: Patients with cardiac devices were less likely to undergo revascularization for STEMI within guideline mandated timeframes. They remain at elevated risk of all-cause mortality up to 5-years compared with STEMI patients without cardiac devices.
- 6 October 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (3) , 822-837
Inequalities in Gastrointestinal Care Provision in the United Kingdom
Background Gastrointestinal (GI) and liver diseases impose a substantial burden on the United Kingdom’s health system, ranking among the leading causes of mortality, cancer-related deaths, and hospital admissions. Despite the universal framework of the National Health Service (NHS), profound inequalities persist across socioeconomic, geographic, and ethnic lines. Objectives This review focuses on colorectal cancer (CRC) and hepatocellular carcinoma (HCC) as exemplar conditions, synthesising current evidence on disparities across the care continuum and exploring strategies to mitigate them. Methods Current national data and published evidence were reviewed to assess inequities in disease prevalence, access to care, and outcomes across socioeconomic strata, regions, and ethnic groups. The analysis also examined workforce distribution, policy frameworks, and emerging interventions aimed at addressing these disparities. Results Disease prevalence and outcomes are markedly worse in socioeconomically deprived regions; liver disease mortality is more than twice as high in the poorest deciles, and CRC survival is significantly lower among disadvantaged populations. Access to care remains uneven—deprived groups exhibit lower CRC screening uptake, delayed diagnoses, and higher emergency presentation rates. Routine HCC surveillance in at-risk patients is inconsistently delivered. Workforce shortages and maldistribution exacerbate these inequities, with under-resourced regions facing longer waiting times and limited specialist access. Systemic challenges, including social determinants, data deficits, and policy underprioritisation, further hinder progress. Emerging Developments Promising advances include the NHS’s expansion of community diagnostic centres, targeted workforce investment, national hepatitis C virus (HCV) elimination programmes, and structural interventions such as minimum unit pricing for alcohol. Technological innovations—including non-invasive diagnostics and digital tools—offer additional opportunities to bridge care gaps. Conclusions Targeted actions, such as implementing primary care FibroScan services, CRC outreach initiatives with GP endorsement, and patient navigation for HCC surveillance, are critical to reducing inequalities and improving outcomes. By addressing upstream determinants and ensuring that innovations reach under-served populations, the UK can progress toward reducing GI health inequalities, improving outcomes, and achieving more uniform digestive health across all communities.
- 6 October 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (3) , 822-837
Inequalities in Gastrointestinal Care Provision in the United Kingdom
Background Gastrointestinal (GI) and liver diseases impose a substantial burden on the United Kingdom’s health system, ranking among the leading causes of mortality, cancer-related deaths, and hospital admissions. Despite the universal framework of the National Health Service (NHS), profound inequalities persist across socioeconomic, geographic, and ethnic lines. Objectives This review focuses on colorectal cancer (CRC) and hepatocellular carcinoma (HCC) as exemplar conditions, synthesising current evidence on disparities across the care continuum and exploring strategies to mitigate them. Methods Current national data and published evidence were reviewed to assess inequities in disease prevalence, access to care, and outcomes across socioeconomic strata, regions, and ethnic groups. The analysis also examined workforce distribution, policy frameworks, and emerging interventions aimed at addressing these disparities. Results Disease prevalence and outcomes are markedly worse in socioeconomically deprived regions; liver disease mortality is more than twice as high in the poorest deciles, and CRC survival is significantly lower among disadvantaged populations. Access to care remains uneven—deprived groups exhibit lower CRC screening uptake, delayed diagnoses, and higher emergency presentation rates. Routine HCC surveillance in at-risk patients is inconsistently delivered. Workforce shortages and maldistribution exacerbate these inequities, with under-resourced regions facing longer waiting times and limited specialist access. Systemic challenges, including social determinants, data deficits, and policy underprioritisation, further hinder progress. Emerging Developments Promising advances include the NHS’s expansion of community diagnostic centres, targeted workforce investment, national hepatitis C virus (HCV) elimination programmes, and structural interventions such as minimum unit pricing for alcohol. Technological innovations—including non-invasive diagnostics and digital tools—offer additional opportunities to bridge care gaps. Conclusions Targeted actions, such as implementing primary care FibroScan services, CRC outreach initiatives with GP endorsement, and patient navigation for HCC surveillance, are critical to reducing inequalities and improving outcomes. By addressing upstream determinants and ensuring that innovations reach under-served populations, the UK can progress toward reducing GI health inequalities, improving outcomes, and achieving more uniform digestive health across all communities.
- Open Access
- 16 September 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-10
Sterile water injections for analgesia in renal colic: a meta-analysis of level 1 evidence
Objective: To evaluate the effectiveness of Sterile water injections (SWIs) for acute pain relief in renal colic. Methods: This study was conducted in accordance with the Preferred Reporting items for Systematic Reviews and Meta-Analyses. MEDLINE, CINAHL, Web of Science and Cochrane were searched to identify randomised controlled trials (RCTs) comparing SWIs with placebo or other analgesics in renal colic patients. Data were pooled and analysed using random effects modelling with 95% confidence intervals (CIs). Results: Six RCTs including 1322 renal colic patients were included, with 466 (35.2%) receiving SWIs. Patients receiving SWIs had comparable demographics and presenting features to the control groups, with control medications ranging from placebos, non-steroidal anti-inflammatories, and opioids. Self-reported pain scores at 30 min following intervention were lower in SWI than placebo (MD = − 4.63, 95% CI: − 5.16, − 4.10, P < 0.001) and other analgesics (MD = − 0.36, 95% CI: − 0.52, − 0.21, P < 0.001). The use of rescue analgesia was lower in those receiving SWIs compared to placebo (OR = 0.24, 95% CI: 0.10, 0.59, P = 0.002) and other analgesics (OR = 0.46, 95% CI: 0.29, 0.74, P = 0.001). No significant side effects were attributed to SWI use. Conclusions: SWIs demonstrated superior pain relief and reduced rescue analgesia requirements, compared to placebo and standard treatment, offering a promising alternative for patients where traditional options are unsuitable.
- 16 September 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-10
Open AccessSterile water injections for analgesia in renal colic: a meta-analysis of level 1 evidence
Objective: To evaluate the effectiveness of Sterile water injections (SWIs) for acute pain relief in renal colic. Methods: This study was conducted in accordance with the Preferred Reporting items for Systematic Reviews and Meta-Analyses. MEDLINE, CINAHL, Web of Science and Cochrane were searched to identify randomised controlled trials (RCTs) comparing SWIs with placebo or other analgesics in renal colic patients. Data were pooled and analysed using random effects modelling with 95% confidence intervals (CIs). Results: Six RCTs including 1322 renal colic patients were included, with 466 (35.2%) receiving SWIs. Patients receiving SWIs had comparable demographics and presenting features to the control groups, with control medications ranging from placebos, non-steroidal anti-inflammatories, and opioids. Self-reported pain scores at 30 min following intervention were lower in SWI than placebo (MD = − 4.63, 95% CI: − 5.16, − 4.10, P < 0.001) and other analgesics (MD = − 0.36, 95% CI: − 0.52, − 0.21, P < 0.001). The use of rescue analgesia was lower in those receiving SWIs compared to placebo (OR = 0.24, 95% CI: 0.10, 0.59, P = 0.002) and other analgesics (OR = 0.46, 95% CI: 0.29, 0.74, P = 0.001). No significant side effects were attributed to SWI use. Conclusions: SWIs demonstrated superior pain relief and reduced rescue analgesia requirements, compared to placebo and standard treatment, offering a promising alternative for patients where traditional options are unsuitable.
- Open Access
- 28 August 2025
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 25 (10) , 1350-1358
Emergency department attendance stratified by cause and frailty status: A national retrospective cohort study
Aim: The aim of this study was to determine whether the causes of emergency department (ED) attendance and clinical outcomes vary by frailty status.Methods: Using the Nationwide ED Sample, causes of attendance were stratified by Hospital Frailty Risk Score (HFRS). Logistic regression was used to determine adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs) of ED and overall mortality.Results: A total of 155 497 048 ED attendances were included, of which 125 809 960 (80.9%) had a low HFRS (15). The most common cause of ED attendance in the high‐HFRS group was infectious diseases (43.0%), followed by cardiovascular diseases (CVD) (24.0%) and respiratory diseases (10.2%). For the low‐HFRS group, musculoskeletal disease was the most common cause (21.2%), followed by respiratory diseases (20.6%) and gastrointestinal diseases (18.5%). On adjusted analysis, high‐HFRS attendances had increased overall mortality (combined ED and in‐hospital) across most attendance causes, compared with their low‐risk counterparts (P < 0.001). High‐HFRS attendances with infectious diseases, CVD, and respiratory diseases had an increased risk of overall mortality, compared with their low‐risk counterparts (aOR 23.88, 95% CI 23.42–24.34 for the infectious disease cohort; aOR 2.58, 95% CI 2.55–2.61 for the CVD cohort; and aOR 36.90, 95% CI 36.18–37.62 for the respiratory disease cohort).Conclusions: Frailty is present in a significant proportion of ED attendances, with the cause varying by frailty status. Frailty is associated with decreased ED and increased overall mortality across most attendance causes. Geriatr Gerontol Int 2025; 25: 1350–1358.
- 28 August 2025
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 25 (10) , 1350-1358
Open AccessEmergency department attendance stratified by cause and frailty status: A national retrospective cohort study
Aim: The aim of this study was to determine whether the causes of emergency department (ED) attendance and clinical outcomes vary by frailty status.Methods: Using the Nationwide ED Sample, causes of attendance were stratified by Hospital Frailty Risk Score (HFRS). Logistic regression was used to determine adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs) of ED and overall mortality.Results: A total of 155 497 048 ED attendances were included, of which 125 809 960 (80.9%) had a low HFRS (15). The most common cause of ED attendance in the high‐HFRS group was infectious diseases (43.0%), followed by cardiovascular diseases (CVD) (24.0%) and respiratory diseases (10.2%). For the low‐HFRS group, musculoskeletal disease was the most common cause (21.2%), followed by respiratory diseases (20.6%) and gastrointestinal diseases (18.5%). On adjusted analysis, high‐HFRS attendances had increased overall mortality (combined ED and in‐hospital) across most attendance causes, compared with their low‐risk counterparts (P < 0.001). High‐HFRS attendances with infectious diseases, CVD, and respiratory diseases had an increased risk of overall mortality, compared with their low‐risk counterparts (aOR 23.88, 95% CI 23.42–24.34 for the infectious disease cohort; aOR 2.58, 95% CI 2.55–2.61 for the CVD cohort; and aOR 36.90, 95% CI 36.18–37.62 for the respiratory disease cohort).Conclusions: Frailty is present in a significant proportion of ED attendances, with the cause varying by frailty status. Frailty is associated with decreased ED and increased overall mortality across most attendance causes. Geriatr Gerontol Int 2025; 25: 1350–1358.